

TALVEY™ (talquetamab)▼ Patient Card

Carry this card with you at all times.

SHOW THIS CARD to any healthcare professional involved in your care and if you go to the hospital

FOLD HERE

Important Safety Information for Patients

TALVEY can cause side effects such as Cytokine Release Syndrome (CRS) and nervous system toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). CRS and ICANS are serious immune reactions that may require immediate medical attention.¹

FOLD HERE

Important Safety Information for Patients

Get medical help straight away if you experience any of the following:

Cytokine Release Syndrome (CRS)

- Fever
- Low blood pressure
- Chills
- Difficulty breathing
- Fatigue
- Headache
- Fast heartbeat
- Increased level of liver enzymes in the blood

Neurologic toxicity, including ICANS

- Feeling less alert
- Feeling disorientated
- Feeling sleepy
- Slow or difficulty thinking
- Altered thinking or decreased consciousness
- Confusion
- Difficulty speaking and understanding speech

FOLD HERE

Important Safety Information for Patients

IMPORTANT TO REMEMBER: Stay close to the location of the healthcare facility where you received your TALVEY therapy for at least 2 days for daily monitoring after administration of all doses of the step-up dosing schedule. If you have any of the symptoms listed on this card, call your doctor or nurse, or seek emergency medical attention right away! These are not all the possible side effects of TALVEY. Tell your doctor if you have any side effect that bothers you or does not go away.

Prescribing Doctor

PRESCRIBING DOCTOR'S NAME: _____
PRESCRIBING DOCTOR'S PHONE NUMBER: _____

HOSPITAL NAME AND ADDRESS: _____
PHONE NUMBER: _____

PATIENT'S NAME

FOLD HERE

Information for Healthcare Team to Fill In

Please give this card to your healthcare team to fill in the information and return to you.

Dates of TALVEY injections (step-up dosing schedule):

STEP-UP DOSE 1

STEP-UP DOSE 2

STEP-UP DOSE 3

STEP-UP DOSE 4*

TREATMENT PHASE*

*For the biweekly dosing only.

*For the weekly dosing this is: 0.4 mg/kg once every week thereafter.

For the biweekly dosing this is: 0.8 mg/kg once every two weeks thereafter.

FOLD HERE

Important Safety Information for Healthcare Professionals

This patient is receiving Talvey (Talquetamab). CRS and neurologic toxicity, including ICANS, may occur in patients receiving TALVEY, and can be fatal or life-threatening.

Assess the patient for signs and symptoms of CRS and ICANS. If your patient reports any signs or symptoms as referenced on this card, please contact the patient's prescribing doctor immediately for further information.

See Summary of Product Characteristics for full details.

FOLD HERE

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects via: HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or email dsafety@its.jnj.com.